EU regulators could order the divestment of the business as soon as next week to punish Illumina for defying their authority and “illegally” acquiring Grail.
EU poised to order Illumina to sell Grail liquid biopsy unit: FT Read More »
The new division will focus on four core policy priorities under Chair Taha Kass-Hout, chief technology officer at GE HealthCare.
AdvaMed elevates digital health center to division, names board Read More »
La ropa inteligente se ha convertido en una tendencia creciente que promete transformar la forma en que vestimos y vivimos. Esta fusión de moda y tecnología está llevando la comodidad, la funcionalidad y el estilo a un nuevo nivel. La Evolución de la Ropa Intelig …
Ropa inteligente: La revolución tecnológica que viste el futuro Read More »
The search capabilities work alongside Google’s healthcare-focused large language model, Med-PaLM 2, connecting to outside sources and the patient’s medical record.
Google Cloud tunes generative AI for medical search capabilities Read More »
Cryoport, Inc. and the Cell and Gene Therapy Catapult (“CGT Catapult”), an independent innovation and technology organisation specializing in the advancement of cell and gene therapies, today announced the organisations have entered into a new strategic partnership to support the advancement of cell and gene therapies.
Dompé today announced the appointment of Shannon K. Sullivan as Chief Commercial Officer (CCO), effective immediately.
Dompé farmaceutici Appoints Shannon K. Sullivan as Chief Commercial Officer Biotech Read More »
ValGenesis, Inc and Valspec, a global provider of system validation and lifecycle services, have partnered to extend a suite of sophisticated ValGenesis products for life sciences clients in the U.S.
ValGenesis Announces Strategic Partnership with Valspec Read More »
Athersys, Inc. announces that the independent data safety monitoring board (DSMB) has completed a pre-planned interim analysis of the Company’s ongoing Phase 3 MASTERS-2 pivotal clinical trial evaluating MultiStem ® for the treatment of acute moderate-to-severe ischemic stroke, and concluded that the current sample size of 300 patients is insufficiently powered to achieve the primary
Merck, known as MSD outside of the United States and Canada, announced that new data for four approved medicines and three pipeline candidates in more than 15 types of cancer will be presented at the European Society for Medical Oncology Congress 2023 in Madrid, Spain, from Oct. 20-24.
Mallinckrodt plc announced the publication of two journal manuscripts reinforcing the clinical and economic evidence supporting the efficacy, safety profile, continued use, and cost-effectiveness of Acthar Gel for appropriate patients across a range of FDA-approved autoimmune and inflammatory disease indications.
